Clinical Comprehensive Guide: Superior Limbic Keratoconjunctivitis (SLK)

1. Introduction and Clinical Overview

Superior Limbic Keratoconjunctivitis (SLK), first described by Theodore in 1963, is a chronic, recurrent, inflammatory ocular surface disease that primarily affects the superior bulbar conjunctiva, the superior limbus, and the superior cornea. While often misdiagnosed as chronic allergic conjunctivitis or refractory dry eye syndrome, SLK represents a distinct clinical entity characterized by localized inflammation and keratinization.

The condition is notoriously frustrating for both patients and clinicians due to its recalcitrant nature. It typically presents as a bilateral (though often asymmetric) process involving the superior ocular surface. Understanding the pathophysiology is essential for effective management, as the mechanical friction between the upper eyelid and the superior globe is a primary driver of the disease process.

2. Pathophysiology and Mechanisms

The hallmark of SLK is the mechanical-inflammatory feedback loop. The pathophysiology is generally attributed to the following mechanisms:

The Mechanical Friction Hypothesis

The most widely accepted theory involves mechanical trauma. A tight upper eyelid (often associated with thyroid-related lid retraction or anatomical variants) creates excessive friction against the superior bulbar conjunctiva. This chronic mechanical rubbing leads to:
* Squamous Metaplasia: Transformation of the conjunctival epithelium.
* Keratinization: The formation of keratin deposits on the superior limbus.
* Inflammatory Cascade: Release of cytokines (IL-6, IL-8, and TNF-alpha) due to epithelial stress.

The Thyroid Connection

There is a profound, well-documented association between SLK and thyroid dysfunction (specifically hyperthyroidism/Graves' disease). Approximately 30% to 50% of patients with SLK exhibit some form of thyroid abnormality. The mechanism is believed to be secondary to the proptosis and lid retraction associated with thyroid eye disease, which increases the exposure and mechanical stress on the superior conjunctiva.

3. Clinical Presentation and Staging

Standard Presentation

Patients typically present with complaints of:
* Foreign body sensation (often described as "grittiness").
* Burning and ocular fatigue.
* Excessive tearing (epiphora).
* Photophobia.
* Mucoid discharge.

Clinical Signs

Examination under a slit lamp reveals:
1. Superior Bulbar Conjunctival Injection: Hyperemia localized to the superior aspect.
2. Superior Limbic Keratitis: Fine punctate epithelial erosions (PEE) at the superior limbus.
3. Superior Conjunctival Papillary Hypertrophy: A "velvety" appearance of the superior tarsal conjunctiva.
4. Filamentary Keratitis: Formation of mucous/epithelial filaments on the superior cornea.

Grading System (The SLK Severity Index)

4. Differential Diagnosis

Distinguishing SLK from other ocular surface diseases is critical for appropriate treatment.

• Chronic Allergic Conjunctivitis: Unlike SLK, allergy typically involves the inferior conjunctiva more heavily and is associated with intense pruritus (itching).
• Dry Eye Disease (KCS): While SLK and KCS overlap, KCS typically shows inferior corneal staining and lacks the superior bulbar keratinization seen in SLK.
• Trachoma: Features superior pannus and Herbert’s pits, which are distinct from the localized keratinization of SLK.
• Contact Lens-Induced Papillary Conjunctivitis (CLPC): Often mimics the papillary reaction of SLK but is strictly tied to lens wear.

5. Diagnostic Testing Protocols

To confirm a diagnosis of SLK, the clinician should employ the following diagnostic battery:

1. Vital Dye Staining: Use Rose Bengal or Lissamine Green. These dyes are superior to Fluorescein for identifying devitalized, keratinized cells in the superior limbal region.
2. Slit Lamp Biomicroscopy: Eversion of the upper eyelid is mandatory to assess the tarsal conjunctiva for papillary hypertrophy.
3. Thyroid Function Panel: Due to the strong association, serum TSH, T3, and T4 levels must be ordered for any patient presenting with SLK.
4. Impression Cytology (Research/Severe cases): Confirms squamous metaplasia and keratinization at the cellular level.

6. Management and Therapeutic Strategies

Management is tiered based on severity.

Tier 1: Conservative/Supportive

• Preservative-Free Artificial Tears: Frequent lubrication to reduce friction.
• Punctal Plugs: To increase ocular surface moisture.
• Lid Hygiene: Warm compresses to improve meibomian gland function.

Tier 2: Pharmacological Intervention

• Topical Steroids: Short-term use of Loteprednol or Dexamethasone to dampen acute inflammation.
• Topical Cyclosporine A (0.05% or 0.1%): Excellent for long-term management of chronic surface inflammation.
• Acetylcysteine (10%): Used to dissolve filaments if they are causing significant discomfort.

Tier 3: Surgical/Interventional

• Silver Nitrate Application: Topical application (0.5%–1.0%) to the superior bulbar conjunctiva. This acts as a chemical cautery to disrupt the abnormal epithelium.
• Conjunctival Resection: Surgical excision of the diseased superior conjunctiva.
• Thermal Cautery: Applied to the superior bulbar conjunctiva.

7. Risks, Side Effects, and Contraindications

• Steroid-Induced Glaucoma/Cataracts: Long-term use of topical steroids carries significant risks. Regular intraocular pressure (IOP) monitoring is required.
• Chemical Burn Risks: Improper application of silver nitrate can lead to conjunctival scarring or corneal toxicity.
• Surgical Complications: Conjunctival resection carries risks of symblepharon formation if not performed by an expert.

8. Frequently Asked Questions (FAQ)

Q1: Is Superior Limbic Keratoconjunctivitis contagious?
No, SLK is an inflammatory, non-infectious condition. It cannot be transmitted through contact.

Q2: Can contact lenses cause SLK?
While not the primary cause, contact lens wear can exacerbate symptoms by increasing mechanical friction on the superior ocular surface.

Q3: How long does treatment usually take?
SLK is a chronic condition. While symptoms may improve within weeks of starting treatment, management often spans months or years.

Q4: Is there a permanent cure?
For many, surgical intervention (conjunctival resection) provides long-term relief, but recurrence is possible if underlying triggers (like thyroid disease) are not managed.

Q5: Why is my eye always red at the top?
The redness in SLK is caused by chronic inflammation and the tugging of the eyelid against the superior globe.

Q6: Should I stop wearing eye makeup if I have SLK?
Yes, it is highly recommended to avoid cosmetics during a flare-up, as preservatives and particulates can further irritate the inflamed conjunctiva.

Q7: Does SLK lead to blindness?
Blindness is extremely rare. However, if left untreated, chronic keratinization and filamentary keratitis can cause significant corneal scarring, which may impair visual acuity.

Q8: Are there specific diets that help?
While no specific diet cures SLK, an anti-inflammatory diet rich in Omega-3 fatty acids may help improve overall ocular surface health.

Q9: What is the significance of the "velvety" appearance?
This describes papillary hypertrophy, which indicates a chronic immune-mediated response to the mechanical irritation occurring under the eyelid.

Q10: Is surgery a first-line treatment?
No. Surgery is generally reserved for patients who have failed to respond to at least 3–6 months of conservative and topical medical therapy.

9. Long-term Prognosis

The prognosis for SLK is generally favorable with consistent management. However, patients must be informed that the condition is prone to recurrence. The primary factor in long-term success is the management of the underlying mechanical stimulus—whether that involves treating thyroid eye disease, optimizing lid closure, or surgically altering the superior conjunctiva to remove the inflammatory focus.

Regular follow-up with an ophthalmologist or cornea specialist is essential to prevent the progression of corneal filaments and to monitor for potential side effects of long-term medication use. By addressing the mechanical friction and the inflammatory environment concurrently, most patients can achieve a high quality of life and symptomatic relief.